home > news > detailed info

‘Privates Leading the Disruption in Healthcare’ Conference


David MacMurchy, CEO and Robert Jones, Chief Financial Officer, Lightship, a leading provider of virtual-first and hybrid clinical research services, are presenting at a Goldman Sachs on-campus global event on the changing role of clinical trial developm

NEW YORK, NY – APRIL 7, 2022 – David MacMurchy, CEO and Robert Jones, Chief Financial Officer, Lightship, are providing key insights into how precision medicine is changing the landscape of clinical trial development at Goldman Sach’s invitation only event “The New Guard: Privates Leading the Disruption in Healthcare” on April 7th. Lightship is a global virtual-first and hybrid clinical research services provider.

Mr. MacMurchy and Mr. Jones are panelists on “Precision Trials for Precision Medicine: A New Age of Clinical Development,” with other clinical research stakeholders. Topics being discussed include how the clinical research paradigm is changing, leveraging technology to improve clinical trial processes and the evolving role of targeted therapeutics.

“We are looking forward to sharing how Lightship is creating access for patients by breaking down barriers to clinical research participation,” says David MacMurchy. “Scaling inclusion for underrepresented people is essential to developing new medications, treatments and therapies.”

“The concept of decentralized clinical trials is evolving, and Lightship’s approach is to provide patients with choice about where they can receive their clinical research care,” says Robert Jones.
phone +1-855-544-4820
email 222 Pacific Coast Highway El Segundo, CA 90245
Print this page
Send to a friend
News and Press Releases

va-Q-tec: Global specialist for TempChain transport solutions and energy efficiency continues on successful track in the first half of 2022

Würzburg, 11 August, 2022. va-Q-tec AG (ISIN DE0006636681 / WKN 663668), a pioneer in highly efficient products and solutions in the thermal insulation (so-called super insulation) and temperature-managed supply chains (so-called TempChain logistics) area, continued on its past quarters’ profitable growth path in the first half of 2022. Revenue growth in the first half of 2022 was very gratifying overall despite the challenging macroeconomic environment, thanks to the highly sought-after product and service portfolio.
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement